Form MD4, the Medical Device Rules, 2016.: Form MD4
the Medical Device Rules, 2016. - Form MD4
Text of form MD4
Form MD4.
Form MD4.
(3) Where any manufacturer intends to manufacture Class C or Class D medical
device along with Class A or Class B medical device, an application shall be made
to the Central Licensing Authority through an identified online portal of the Central
Government for licence to manufacture for sale or for distribution in Form MD4.
(4) The application in Form MD4 referred in sub-rule (2), relating to Class A
medical devices referred under sub-rule (4) of rule 5, shall be accompanied with a
13
fee as specified in the Second Schedule along with documents specified in clause
(i) of Part II of the Fourth Schedule.
(5) The application in Form MD3 or Form MD4 referred in sub-rule (1), (2) and
(3), relating to Class B, Class C or Class D medical device, as the case may be,
shall be accompanied with a fee as specified in the Second Schedule along with
documents as specified in clause (ii) of Part II of the Fourth Schedule.
(6) The Central Licensing Authority may, wherever required, in case of Class C or
Class D medical device, use the services of experts for matters relating to
inspection or review of the documents:
Provided that the powers and functions under this rule shall be
exercised by the Central Licensing Authority till such time the Central Government
is satisfied that the requisite technical competence has been acquired by the State
Licensing Authority.
Loan licence to
manufacture for sale
and distribution.
16. (1) An application for grant of loan licence to manufacture for sale or
distribution of Class A medical device referred under sub-rule (4) of rule 5, or Class
B medical devices, as the case may be, shall be made to the State Licensing
Authority in Form MD5 accompanied with fee as specified in the Second Schedule
along with documents as specified in clause (i) of Part II or clause (ii) of Part II of
the Fourth Schedule, as the case may be.
(2) An application for grant of loan licence to manufacture for sale or for
distribution of Class C or Class D medical devices, as the case may be, shall be
accompanied with a fee as specified in the Second Schedule along with documents
as specified in clause (ii) of Part II of the Fourth Schedule including details of the
constitution of the firm, manufacturing premises plan or layout, full particulars of
competent and regular technical staff, artwork of product literature, package insert
or instruction for use, proposed device labels, shall be made to the Central
Licensing Authority in Form MD6.
(3) Where any manufacturer intends to manufacture Class C or Class D medical
device along with Class A or Class B medical device, an application for grant of
loan licence shall be made as per sub-rule (3) of rule 15 to the Central Licensing
Authority in Form MD6.
(4) The Central Licensing Authority may, wherever required, in case of Class A,
Class B, Class C or Class D medical device, use the services of external agencies
or bodies for matters relating to inspection or review of documents.
Conditions to be
complied before
grant of
manufacturing
licence or loan
licence.
17. Before grant of licence or loan licence, the following conditions shall be
complied with by the applicant,-
(i) Manufacturing activity of medical device shall be undertaken only under the
direction and supervision of competent technical staff and who has,-
14
(a) degree in engineering (in appropriate branch) or in pharmacy or in science in
appropriate subject and shall have experience of not less than two years; or
(b) diploma in engineering (in appropriate branch) or in pharmacy and shall have
the experience of not less than four years in manufacturing of medical
devices.
(ii) The testing shall be conducted under the direction and supervision of the
competent technical staff having degree or diploma in engineering in appropriate
branch or in pharmacy or in science in appropriate subject and shall have the
experience of not less than two years in testing of medical devices.
(iii) The manufacturing site shall comply with the requirements of the Fifth
Schedule.
Audit or inspection
before grant of
licence for
manufacture.
18. Before grant of licence under this part,-
(i) in respect of Class A medical device referred under sub-rule (4) of rule 5or
Class B medical devices, the establishment where manufacture of such
device is proposed to be undertaken shall be audited by the Notified Body;
(ii) in respect of Class C or Class D medical devices, the establishment in which
the manufacture is or proposed to be undertaken shall be inspected by the
Medical Device Officer with or without an expert in the concerned field for
adequacy and suitability;
Report by Medical
Device Officer or
Notified Body.
19. (1) The Notified Body shall forward a detailed descriptive report giving
findings on each aspect of audit along with recommendations after completion of
audit in accordance with the provisions of rule 18, to the State Licensing Authority
or Central Licensing Authority, as the case may be, through online portal of the
Government referred in rule 15, with a copy to the manufacturer.
(2) The Medical Device Officer shall forward a detailed descriptive report giving
findings on each aspect of inspection along with recommendations after completion
of inspection in accordance with the provisions of rule 18, to the Central Licensing
Authority, through online portal of the Central Government referred in rule 15, with
a copy to the manufacturer.
Grant of licence to
manufacture for sale
and distribution of
medical device.
20. (1) If the State Licensing Authority or the Central Licensing Authority, as the
case may be, after such further enquiry, if any, as may be considered necessary, is
satisfied that the requirements of these rules have been complied with, it shall issue
a licence in Form MD7, or loan licence in Form MD8, as the case may be:
Provided that where a manufacturing licence has been granted to any
manufacturer under Drugs and Cosmetics Rules, 1945, before the date of
commencement of these rules, such manufacturing licence shall be deemed to have
been granted as licence under the provision of these rules for the remaining period
of the said licence.
(2) If the State Licensing Authority or the Central Licensing Authority, as the case
may be, is not satisfied, it may reject the application and shall inform the applicant
15
of the reasons in writing for such rejection.
Conditions for
manufacturing
licence or loan
licence.
21. After the grant of licence or loan licence, the licence holder shall comply with
the following conditions, namely:-
(i) licence shall be kept on the approved premises and shall be produced when
requested by the Medical Device Officer;
(ii) the licence holder shall inform about the occurrence of any suspected
unexpected serious adverse event and action taken thereon including any
recall to the State Licensing Authority or Central Licensing Authority, as the
case may be, within 15 days of such event being brought to the notice of
licence holder;
(iii) the licence holder shall inform forthwith any major change as specified in the
Sixth Schedule to the State Licensing Authority or Central Licensing
Authority, as the case may be, for its approval;
(iv) the licence holder shall inform forthwith any minor change as specified in the
Sixth Schedule to the State Licensing Authority or Central Licensing
Authority, as the case may be;
(v) the licence holder shall inform the State Licensing Authority or the Central
Licensing Authority, as the case may be, in writing within a period of thirty
days in the event of change other than change of constitution of the
manufacturer or change referred in condition (iii) above. The manufacturer
shall submit the confirmation that no changes in specification, labelling or
technical staff has been made;
(vi) the licence holder shall carry out test of each batch of final product prior to its
release for compliance to specification either in his own testing centre or in
any accredited testing centre and shall maintain records of such tests for a
period of one year after expiry of the medical device;
(vii) the licence holder shall, on being informed by the Central Licensing
Authority or State Licensing Authority, as the case may be, that any part of
any lot of the medical device has been found by the licensing authority not
conforming with the provisions specified under the rules and on being
directed so to do, withdraw the remainder of that lot from sale and, so far as
may, in the particular circumstances of the case, be practicable, recall the
issues already made from that lot;
(viii) the licence holder shall maintain an audit or inspection book in Form MD9 to
enable notified body or medical device officer to record his impressions and
the defects noticed;
(ix) the licence holder shall maintain at least two units of samples from each batch
of the invasive medical device manufactured by him for reference purpose.
(x) the license holder shall maintain records of manufacturing and sales which
shall be open to inspection by a medical device officer.
16
(xi) the licence holder shall supply the medical device for sale, offer for sale along
with its package insert.
(xii) in case if the manufacturer has closed down the manufacturing site, the same
shall be intimated to the Central Licensing Authority or State Licensing
Authority, as the case may be.
Fresh Application in
case of change in
constitution.
22. In case of change in constitution after grant of licence under rule 20, the
manufacturer shall make an application under rule 15 for grant of licence within a
period of ninety days from the date of such change in constitution:
Provided that the existing licence shall be deemed to be valid till
such time, a fresh licence is issued or application is rejected by the State Licensing
Authority or the Central Licensing Authority, as the case may be.
Unannounced audit
by State Licensing
Authority.
23. The State Licensing Authority shall have at least two per cent. of the cases of
licence recommended by every Notified Body annually, audited by its officers, and
such cases shall be selected on a random basis.
Duration of licence. 24. (1) A licence or loan licence shall remain valid, unless, it is suspended or
cancelled, provided the licence holder deposits a licence retention fee as specified
in the Second Schedule in every five years from the date of its issue.
(2) If the licence holder fails to pay licence retention fee on or before the due date
as referred to in sub-rule (1), he shall be liable to pay licence retention fee along
with a late fee calculated at the rate of two per cent. of the licence fee for every
month or part thereof up to six months, in the event of non-payment of such fee,
the licence shall be deemed to have been cancelled.
Suspension and
cancellation of
manufacturing
licence.
25. (1) Where the licence holder contravenes any provision of these rules, the State
Licensing Authority or the Central Licensing Authority, as the case may be, may,
after giving the licence holder an opportunity to show cause why such an order
should not be passed, shall by an order in writing including the reasons thereof
suspend it for such period as it thinks fit either wholly or in respect of any of the
medical device or cancel the licence or loan licence.
(2) A licence holder whose licence or loan licence has been suspended or cancelled
by the State Licensing Authority or Central Licensing Authority, as the case may
be, under sub-rule (1), may within sixty days of the receipt of a copy of the order
by him, prefer an appeal to the State Government or Central Government, as the
case may be, and State Government or the Central Government, as the case may
be, may after giving the licence holder an opportunity of being heard, confirm,
reverse or modify such order.
(3) Any licence suspended in accordance with these rules shall not be revoked by
the State Licensing Authority or the Central Licensing Authority without a detailed
written order indicating the reasons for such suspension and the extent of
compliance vis-à-vis the deficiencies that led to suspension and publishing the
order on its website.
17
(4) All orders of suspension issued or revoked or cancellation of licence shall be
duly published on the websites of the State Licensing Authority concerned and the
Central Licensing Authority.
(5) The State Licensing Authority or the Central Licensing Authority, as the case
may be, may order destruction of such stock of medical device in the presence of a
Medical Device Officer, if in its opinion, the licence holder has failed to comply
with any of the conditions of the licence or loan licence or with any provisions of
the Act or rules made thereunder.
Product Standards
for medical device.
26. The medical devices shall conform to the standards,-
(1) laid down by the Bureau of Indian Standards established under section 3 of
the Bureau of Indian Standards Act, 1985 (63 of 1985) or the Central
Government from time to time;
(2) If there is no relevant Standard laid down by the Bureau of Indian Standard
or the Central Government, then it shall conform to the standard laid down
by International Organisation for Standards (ISO) or other Pharmacopeial
standard;
(3) In case, national or international standards are not available, the device shall
conform to the manufacturer’s standards which are validated.
Manufacturing of
medical devices for
clinical
investigation, test,
evaluation,
examination and
demonstration.
27. (1) Small quantity of any class of medical device may be manufactured for
the purpose of clinical investigations, test, evaluation, examination, demonstration
or training for which an application shall be made in Form MD10 to the Central
Licensing Authority and shall be accompanied with a fee as specified in the Second
Schedule.
(2) On receipt of an application for test licence in the form and manner specified in
sub-rule (1) and (2), the Central Licensing Authority shall, on being satisfied, grant
the test licence in Form MD11.
(3) The licensee shall keep a record of, and shall report to the Central Licensing
Authority, the date and quantity of product manufactured under test licence.
Duration of licence
for clinical
investigations, test,
analysis,
demonstration and
training.
28. A licence in Form MD11 shall, unless cancelled earlier, be in force for a
period of three years from the date of issue.
Cancellation of
licence for clinical
investigations, test,
analysis,
demonstration and
training
29. (1) Where the licensee contravenes any provision of these rules, the Central
Licensing Authority may, after giving him an opportunity in writing, to show cause
as to why such an order should not be made, by an order stating the reasons
therefor, suspend for such period as he may be deemed proper, or cancel the test
licence.
(2) Where the licensee is aggrieved by an order made by the Central Licensing
Authority under sub-rule (1), he may, within thirty days of the receipt of the order,
prefer an appeal to the Central Government and that the Central Government may,
after such enquiry as it considers necessary and after affording an opportunity of
18
being heard, issue such order as it may deem proper.
Part V
Import of Medical Devices
Application for issue
of licence of
overseas
manufacturing site
and import of
medical device.
30. (1) The Central Licensing Authority shall have the powers to grant licence
and perform other related functions for import of medical devices specified in sub-
rule (1) and (2) of rule 5.
(2) An authorised agent having, licence to manufacture for sale or licence to sale by
way of wholesale under these rules, shall make an application for import of such
medical device to the Central Licensing Authority in Form MD12 for obtain a
licence.
(3) The application under sub-rule (2) shall be accompanied with fee as specified in
the Second Schedule along with documents as specified in the Part I, II, and III of
the Fourth Schedule:
Provided that any change in the documents submitted at the time of
application and prior to grant of licence shall be notified to the Central Licensing
Authority.
(4) (i) Any subsequent application for grant of licence of additional manufacturing
site made by the same authorised agent shall be accompanied with a fee as referred
in sub-rule (3);
(ii) Any subsequent application for licence of additional medical device made by
the same authorised agent shall be accompanied with the fee as specified in the
Second Schedule for each medical device;
(iii) In case of any subsequent application for grant of licence of different variants
of already registered family is made by the same authorised agent, the additional
fee as specified in the Second Schedule shall be paid for each variant.
(5) A single licence may be granted to an authorised agent in India in respect of one
or more medical devices manufactured at one or more manufacturing sites.
(6) Where the Central Licensing Authority has a reasonable doubt about the quality
of the medical device and decides to subject it to evaluation, test or examination,
the fee as charged by concerned testing Centre shall be paid by the authorised agent
for such evaluation, test or examination directly to the testing laboratory as
specified by the Central Licensing Authority.
(7) Where the original licence is defaced, damaged or lost, the authorised agent
may make an application accompanied with fee as specified under the Second
Schedule for duplicate copy of such licence.
Inspection of
overseas
manufacturing site.
31. The Central Licensing Authority may cause an inspection of the overseas
manufacturing site either by itself or by any other person to whom the power has
been delegated for the purpose and the applicant shall be liable to pay a fee as
specified under the Second Schedule in respect of expenditure required in
connection with the visit to the overseas manufacturing site.
19
Grant of licence of
medical device and
manufacturing site
for import.
32. (1) On receipt of an application under sub-rule (2) of rule 30, the Central
Licensing Authority shall, on being satisfied about the information and the
documents enclosed with the application, grant the licence in Form MD13:
Provided that where licence has been granted to the authorised agent
before the date of commencement of these rules, such licence certificate shall be
deemed to have been granted under the provisions of these rules for the remaining
period of the said licence.
(2) A licence shall be granted under sub-rule (1) if the medical device is having free
sale certificate from the national regulatory authority or competent authority of the
United States of America, European Union countries, Canada, Australia and Japan.
(3) Where the medical device is proposed to be imported from countries other than
those referred to in sub-rule (2), the licence in case of Class C and Class D medical
devices may be granted after its safety and effectiveness has been proved or
established through clinical investigation in India as specified under Part VII of
these rules.
Duration of licence. 33. (1) A licence shall remain valid, unless, it is suspended or cancelled, provided
the authorised agent deposits a licence retention fee as specified in the Second
Schedule for each overseas manufacturing site and for each device in every five
years from the date of its issue
(2) If the authorised agent fails to pay licence retention fee on or before the due
date as referred to in sub-rule (1), he shall be liable to pay licence retention fee
along with a late fee calculated at the rate of two per cent. of the licence retention
fee for every month or part thereof up to six months and thereafter the licence shall
be deemed to have been cancelled.
Conditions to be
complied with by
authorised agent.
34. The licence holder shall comply with the following conditions, namely:-
(i) The licence shall be kept and made available in the licensed premises;
(ii)The authorised agent shall inform the licensing authority forthwith in the event
of any administrative action taken due to adverse reaction, viz. Market withdrawal,
regulatory restrictions, cancellation of authorisation or not of standards quality
report of any medical device pertaining to this licence declared by the regulatory
authority of the country of origin or by any regulatory authority of any other
country, where the medical device is marketed, sold or distributed;
(iii) The authorised agent in cases referred in condition (ii), shall stop immediately
the dispatch and marketing of the medical device;
(iv) The Central Licensing Authority after due consideration may issue directions in
respect of marketing, sale or distribution of the medical device referred in condition
(iii) including withdrawal of medical device from Indian market within a specified
time period;
(v) The authorised agent shall obtain prior approval from the Central Licensing
Authority in case of any change in the intended use or any major change as
20
specified in the Sixth Schedule of medical devices classified under Class B, Class C
or Class D;
(vi) the authorised shall inform forthwith any minor change as specified in the
Sixth Schedule to the State Licensing Authority or Central Licensing Authority, as
the case may be;
(vii) The authorised agent shall inform the Central Licensing Authority in writing
within a period of thirty days in the event of any change in the constitution of the
overseas manufacturer or the authorized agent;
(viii) Where the Central Licensing Authority is satisfied that the sample of any
medical device is not in conformity with the provisions of these rules, it may issue
direction for not to sell or offer for sale, or to recall or withdraw, such medical
device;
(ix) the consignment of medical device shall be accompanied by an invoice or
statement showing the name and address of the manufacturer and the name and
quantity of medical device.
(x) the licence holder shall supply the medical device for sale, offer for sale along
with its package insert.
Fresh Application in
case of change in
constitution.
35. In case of change in constitution after grant of licence under rule 32, the
importer shall make an application under rule 30 for grant of licence within a
period of ninety days from the date of such change in constitution:
Provided that the existing licence shall be deemed to be valid till
such time, the fresh licence is issued or application is rejected by the Central
Licensing Authority.
Test licence for
import for the
purpose of clinical
investigations, test,
evaluation,
demonstration or
training
36. (1) Medical device or in vitro diagnostic medical device, the import of which is
otherwise not approved, may be allowed by the Central Licensing Authority to be
imported in such quantities as may be necessary for the purpose of clinical
investigations, test, evaluation, and demonstration or training.
(2) The quantity considered necessary shall be determined by the Central Licensing
Authority after taking into account the clinical investigation or approved clinical
investigation plan or information and documents submitted by the applicant.
(3) An application for an import licence for test, evaluation or demonstration or
training shall be made to the Central Licensing Authority in Form MD14 and shall
be accompanied by the fee as specified in the Second Schedule.
(4) On receipt of an application under sub-rule (2), the Central Licensing Authority
shall, on being satisfied about the contents and the documents enclosed with the
application, grant the test licence in Form MD15.
(5) The medical device for which the test licence is granted under sub-rule (4),
shall, be used exclusively for purposes of clinical investigation, test, evaluation,
demonstration or training, as the case may be, and such clinical investigations, test,
evaluation, demonstration or training, shall be conducted in the place specified in
21
such test licence.
(6) The holder of test licence shall maintain record of the activities undertaken
including the name of manufacturer, quantity imported and date of import.
(7) The consignment of medical device shall be accompanied by an invoice or
statement showing the name and address of the manufacturer and the name and
quantity of medical device.
(8) A licence in Form MD15 shall, unless cancelled earlier, be in force for a period
of three years from the date of issue.
(9) The medical devices including in vitro diagnostic medical device referred in
sub-rule (5) that are not used may be permitted to be exported or destroyed under
intimation to the Central Licensing Authority.
Import of
investigational
medical device by
Government
hospital or statutory
medical institution
for treatment of
patient.
37. (1) Small quantity of investigational medical device, the import of which is
not allowed, but approved in the country of origin, may be allowed to be imported
by the Central Licensing Authority for treatment of a patient suffering from a life
threatening disease or disease causing serious permanent disability or disease
requiring therapy for unmet medical need, on an application made by the Medical
Officer through the medical superintendent of a Government hospital or a statutory
medical institution in Form MD16 and such application shall be accompanied by
documents required and the fee as specified in the Second Schedule.
(2) On receipt of an application under sub-rule (1), the Central Licensing Authority
shall, on being satisfied about the information and the documents enclosed with the
application, grant the import licence for treatment of patient in Form MD17.
(3) The medical device for which the licence is granted under sub-rule (2), shall,
be used exclusively for the purpose of treatment of patient declared in the
application.
(4) The holder of licence shall maintain record of activities undertaken including
the name of the manufacturer, quantity imported and used, date of import, name
and address of the patient and diagnosis.
(5) The holder of licence shall allow the medical device officer authorised by the
Central Licensing Authority in this behalf to enter, with or without prior notice, the
premises where the medical devices are stocked and to inspect the premises and
relevant records and investigate the manner in which the medical device is being
used and to take, if required, samples thereof.
(6) The quantity considered necessary shall be determined by the Central Licensing
Authority after taking into account the treatment of patient suffering from a life
threatening disease or disease causing serious permanent disability or disease
requiring therapy for unmet medical need
(7) Where the Central Licensing Authority is satisfied, it may, in exceptional and
special circumstances allow the import of larger quantity of medical devices for
use by the patient.
22
(8) The consignment of medical device shall be accompanied by an invoice or a
statement showing the name and address of the manufacturer and the name and
quantity of medical device.
Import of medical
device for personal
use.
38. (1) Small quantity of medical device, the import of which is not allowed, may
be imported for personal use, on an application made by applicant in Form MD18
which shall be accompanied by documents confirming that the device is for
legitimate personal use.
(2) On receipt of an application under sub-rule (1), the Central Licensing Authority
shall, on being satisfied about the information and the documents enclosed with the
application, grant permission in Form MD19.
(3) The medical device shall be imported subject to the following conditions,
namely:-
(i) the medical device shall be deemed to be part of the baggage of a passenger
or patient and be intended for, the exclusive use of the patient;
(ii) the medical device shall be declared as the personal property to the Customs
Authorities if they so direct ;
(iii) the quantity to be imported is reasonable in the opinion of the Central
Licensing Authority;
(iv) the medical device is prescribed by a registered medical practitioner; and
(v) the consignment of medical device shall be accompanied by an invoice or
statement showing the name and address of the manufacturer and the name and
quantity of medical device.
(4) Where the Central Licensing Authority is satisfied, it may, in exceptional and
special circumstances, allow the import of larger quantity of medical devices for
use by the patient.
Part VI
Labelling of Medical Devices
Labelling of medical
devices.
39. The following particulars shall be printed in indelible ink on the label on the
shelf pack of the medical device or on the outer cover of such medical device and
on every outer covering in which the medical device is packed, namely:-
(a) proper name of medical device;
(b) the details necessary for the user to identify the device and its use;
(c) the name of the manufacturer and address of the manufacturing premises
where the device has been manufactured;
(d) the correct statement of the net quantity in terms of weight, measure, volume,
number of units, as the case may be, and the number of devices contained in the
package, shall be expressed in metric system; and
(e) the date of manufacture and date of expiry; alternately the label shall bear the
shelf life of the product:
Provided that in case of sterile devices, the date of sterilization may
23
be given as the date of the manufacture of the device:
Provided further that when the device is made up of materials such
as stainless steel or titanium and supplied non-sterile, date of expiry may not be
necessary;
Explanation: For the purpose of this rule, the date of expiry shall be in terms of
month and year and it shall mean the medical device is recommended till the last
day of the month. The date of expiry shall be preceded by the words ‘Expiry date’.
(f) to provide, wherever required, an indication that the device contains medicinal
or biological substance;
(g) to provide, a distinctive batch number or lot number preceded by the word “Lot
No.” or “Lot” or “Batch No.” or “B. No.”;
(h) to indicate, wherever required, any special storage or handling conditions
applicable to the device;
(i) to indicate, if the device is supplied as a sterile product, its sterile state and the
sterilisation method;
(j) to give, if considered relevant, warnings or precautions for the attention of the
user of the medical device;
(k) to label the device, if the device is intended for single use;
(l) to overprint on the label of the container, the words “FOR CLINICAL
INVESTIGATION ONLY”, if the device is intended for clinical investigation;
(m) to overprint on the label of the device, the words “Physician’s Sample- Not to
be sold”, if a medical device is intended for distribution to the medical professional
as a free sample;
(n) to provide, except for imported devices, the manufacturing licence number by
preceding the words “Manufacturing Licence Number” or “Mfg. Lic. No.” or “M.
L”;
(o) devices or In-vitro diagnostics which are not sold to customer or patient directly
and are sold for use by hospitals or diagnostic labs shall provide the information
affixing additional label or sticker on outer shelf pack;
(p) to provide unique device identification of the medical device which shall
contain device identifier and production identifier.
Explanation: for the purpose of this rule,-
(i) “device identifier” means global trade item number.
(ii) “production identifier” means serial number, lot or batch number, software
as a medical device version, manufacturing and or expiration date.
(q) to provide on the label, in case of imported devices, with the approval of the
Central Licensing Authority, the import licence number, name and address of the
importer and address of the actual manufacturing premises, date of manufacture, (if
not already printed at the time of import) may be stickered or overprinted on outer
shelf pack:
24
Provided that the label may bear symbols recognised by the Bureau of
Indian Standards or International Organisation for Standardization (ISO) in lieu of
text and the device safety is not compromised by a lack of understanding on the
part of the user in case the meaning of the symbol is not obvious to the device
user.
Provided that all such medical devices on which the information cannot be
printed legibly due to the small size constraints, shall include the information
necessary for product identification and safety viz. information covered by clauses
(a), (b), (e), (g) and (k) above.
Exemption of
certain labelling
requirements for
medical devices for
export from India.
40. The labels on packages or container of devices for export shall be adopted to
meet the specific requirements of law of the country to which the device is to be
exported, but the following particulars shall appear in a conspicuous manner on the
label of the inner most pack of the medical device in which the device is packed
and every other outer covering in which the container is packed:-
(a) name of the Device;
(b) the distinctive batch number or lot number preceded by the word “Lot No.” or
“Lot” or “Batch No.” or “B.No.”;
(c) date of expiry, if any;
(d) the name and address of the manufacturer and address of actual premises where
the device has been manufactured;
(e) licence No. preceded by the letters “Licence No. or Lic. No.”.
(f) internationally recognised symbols in lieu of text, wherever required:
Provided that where a device is required by the consignee not to be
labeled with the name and address of the manufacturer, the label on the packages
or container shall bear a code number as approved by the Central Licensing
Authority and the code number shall bear the name of the State or Union territory,
in abbreviation, followed by the word “Device” and “manufacturing licence
number”.
Provided further that where a device is required by the consignee not to
be labeled with the code number also, the label on the packages or container shall
bear a special code number, as requested by the consignee, and approved by the
licensing authority.
Shelf life of the
medical devices.
41. The shelf life of the medical devices shall not exceed sixty months from the
date of manufacture:
Provided that this period may be extended by the Central Licensing Authority, in
respect of any specified medical device, if satisfactory evidence is produced by the
manufacturer to justify such extension:
Provided that the licensing authority shall not allow the import of any
medical device, whose total shelf life claim is less than three months, having less
than forty per cent. residual shelf-life period as on the date of import.
25
Provided further that the licensing authority shall not allow the import of
any medical device, whose total shelf life claim is between three months and one
year, having less than fifty per cent. residual shelf-life period as on the date of
import.
Provided also that the licensing authority shall not allow the import of any
medical device, whose total shelf life claim is more than one year, having less than
sixty per cent. residual shelf-life period as on the date of import.
Labelling of medical
device import or
manufactured for
purpose of clinical
investigations, test,
analysis,
demonstration and
training.
42. Any medical device imported or manufactured, for the purpose of clinical
investigations, test, evaluation, demonstration and training, shall be kept in
containers bearing labels, indicating name of the product or code number, batch or
lot number, date of manufacture, use before date, storage conditions, name and
address of the manufacturer, and the purpose for which it has been manufactured.
PART VII
CLINICAL INVESTIGATION OF MEDICAL DEVICE AND CLINICAL
PERFORMANCE EVALUATION OF NEW INVITRO DIAGNOSTIC
MEDICAL DEVICE
Conduct of clinical
investigation.
43. No person or sponsor shall conduct any clinical investigation in respect of
investigational medical device in human participants except in accordance with
these rules and in accordance with the permission granted by the Central Licensing
Authority.
Application of Rule
122DD of Drugs
and Cosmetics
Rules, 1945 with
regard of Ethics
Committee.
44. (1) The Ethics Committee constituted under rule 122DD of the Drugs and
Cosmetics Rules, 1945 shall perform the functions and duties under these rules and
shall be deemed to be constituted under these rules.
(2) The other provisions of Ethics Committee provided in rule 122DD of the Drugs
and Cosmetics Rules, 1945 shall be applicable mutatis mutandis, for the purpose of
clinical investigation and clinical performance evaluation under this part.
Application for grant of
permission to conduct
and carry out clinical
investigation.
45. (1) An application for grant of permission to conduct clinical investigation for
investigational medical device shall be made to the Central Licensing Authority in
Form MD20 by a sponsor and shall be accompanied with information specified in
the Seventh Schedule:
Provided, that the investigational medical devices approved for marketing
by United States Food and Drug Administration shall be waived off from the
requirements of the clinical investigation under this Part.
(2) An application for grant of permission to conduct,-
(a) a pilot clinical investigation or first in human study, on an investigational
medical device in India shall be made as referred to in sub-rule (1) accompanied
with fee as specified in the Second Schedule along with the information as
specified in the Seventh Schedule.
(b) a pivotal clinical investigation on an investigational medical device shall be
made on the basis of data emerging from pilot clinical investigation, as referred in
biotech
Highlight
biotech
Highlight
biotech
Highlight
26
sub-rule (1), accompanied with a fee as specified in the Second Schedule:
Provided that no fee shall be paid by any institute, organization, hospital
run or funded by the Central Government or State Government, as the case may be,
for conduct of clinical investigation.
(3) No permission for conduct of academic clinical study on registered or approved
medical device shall be required, where,-
(a) the investigation is approved by the Ethics Committee; and
(b) the data generated shall not be used to furnish it to the Central Licensing
Authority for manufacture or import to market investigational medical device in the
country.
(4) The Central Licensing Authority may, in public interest, abbreviate, defer, or
waive the requirement of conducting clinical investigation for reasons to be
recorded in writing before granting permission to import or manufacture
investigational medical device in the country.
(5) Medical device requiring clinical investigation but claiming substantial
equivalence to a predicate device shall not be marketed unless the Central
Licensing Authority has approved it.
Explanation-. For the purposes of this sub-rule, a device shall be deemed to be
substantially equivalent in comparison to a predicate device, if it has,-
i. the same intended use and technological characteristics; or
ii. same intended use and different technological characteristics and
demonstrate that the device is as safe and effective as the predicate device;
(6) The Central Licensing Authority, after being satisfied with the information
furnished along with application under sub-rule (1), may grant permission to
conduct clinical investigation for an investigational medical device in Form MD21:
Provided that the Central Licensing Authority shall, where the information
including clinical investigation is inadequate as per the Seventh Schedule, intimate
the applicant in writing, within ninety days from the date of application or such
extended period, not exceeding a further period of thirty days, as the Central
Licensing Authority may, for reasons to be recorded in writing, permit, the
conditions which shall be satisfied before permission could be considered:
Provided that if the applicant has not furnished the required information
sought by the Central Licensing Authority, within ninety days from the date of
intimation, it may reject the application for reasons to be recorded in writing.
Condition for
permission.
46. After grant of permission referred in rule 45 the following conditions shall be
complied with by the applicant,-
(i) clinical investigation shall be initiated under the supervision of an approved
Ethics Committee;
(ii) clinical investigation shall be conducted in compliance with the approved
clinical investigation plan, Good Clinical Practices Guidelines and provisions
biotech
Highlight
biotech
Highlight
biotech
Highlight
27
of the Seventh Schedule;
(iii) clinical investigation shall be registered with the Clinical Trial Registry of
India before enrolling the first patient for such clinical investigation;
(iv) annual status report of each clinical investigation, as to whether it is ongoing,
completed or terminated, shall be submitted to the Central Licensing Authority
by the sponsor, and in case of termination of any clinical investigation, the
detailed reasons for the same shall also be communicated to the Central
Licensing Authority within thirty days of such termination;
(v) information about any report of suspected unexpected serious adverse event
occurring during clinical investigation on the subject, shall, after due analysis,
be submitted to the Central Licensing Authority within fifteen days of the
sponsor coming to know about its occurrence as specified in the Seventh
Schedule and in compliance with the procedure specified in these rules.
(vi) in case of an injury or death during clinical investigation of the subject of a
clinical investigation, the applicant shall provide complete medical
management and compensation in case of clinical investigation related injury or
death in accordance with these rules.
(vii) the premises of the sponsor including their employees, subsidiaries and
branches, their agents, contractors and sub-contractors and clinical investigation
sites shall be open to inspection by officers of Central Licensing Authority or
authorised personnel of Notified Bodies under these rules, to verify compliance
of the requirements of these rules for conduct of clinical investigation.
(viii) the clinical investigation shall be initiated by enrolling first patient within the
period of one year from the date of grant of permission, failing which prior
permission from the Central Licensing Authority is required.
(ix) the Central Licensing Authority may impose any other condition while granting
permission in respect of specific clinical investigations, if considered necessary,
regarding the objective, design, subject population, subject eligibility,
assessment, conduct and treatment of clinical investigation.
Suspension or
cancellation of
permission.
47. (1) If any person to whom permission is granted under this part fails to comply
with any of conditions of permission, the Central Licensing Authority may,-
(a) issue warning letter giving details of deficiency found; or
(b) debar the investigator, sponsor including their employees, subsidiaries
and branches, their agents, contractors and sub-contractors to conduct
any clinical investigation in future; or
(c) suspend the permission for such period as it thinks fit or cancel either
wholly or partly to which it relates;
biotech
Highlight
biotech
Highlight
biotech
Highlight
biotech
Highlight
28
(2) Any person who is aggrieved by the order passed under sub-rule (1), may,
within thirty days from the date of receipt of such order, prefer an appeal to the
Central Government, and the Central Government may, after such enquiry into the
matter, as is considered necessary and after giving an opportunity of being heard,
pass such order in relation thereto as, it thinks fit.
Medical management
and compensation for
injury or death related
to clinical
investigation.
48. (1) Where any participant is injured on account of his participation in the
clinical investigation, the sponsor permitted under rule 45 shall provide medical
management to that participant.
(2) Where an injury is caused to the participant in a clinical investigation of any
investigational medical device and such injury is attributable to the use of
investigational medical device, the sponsor permitted under rule 45 shall provide to
that participant, medical management and such compensation in such manner as
specified under rule 122DAB of the Drugs and Cosmetics Rules, 1945 and shall be
applicable mutatis mutandis, for the purpose of medical management and such
compensation in case of clinical investigation and clinical performance evaluation
under this part.
(3) Where death of a participant is related to clinical investigation and is
attributable to the use of an investigational medical device, the sponsor, permitted
under rule 45 shall provide to the legal heir of that participant, such compensation
in such manner as specified under rule 122DAB of the Drugs and Cosmetics Rules,
1945 and shall be applicable mutatis mutandis, for the purpose of such
compensation in case of clinical investigation and clinical performance evaluation
under this part.
Power of Medical
Devices Officer in
respect of clinical
investigation or
clinical performance
evaluation.
49. The Medical Devices Officer, with or without expert, with the prior approval of
the Central Licensing Authority may, with or without prior notice, enter into any
premises related to clinical investigation or clinical performance evaluation to
inspect the facilities, search and seize, record, data, documents, books, and medical
devices including investigational medical devices.
Maintenance of
record and
furnishing
information.
50. Every person, sponsor, clinical research organisation, any other organisation or
investigator conducting a clinical investigation or clinical performance evaluation
or his agent holding a permission under this part shall keep and maintain such data,
record, registers and other documents for a period of twenty years and shall furnish
such information as may be required by the Central Licensing Authority or any
other officer authorised by it in this behalf under rule 49.
Disclosure of name,
address, etc. of
persons involved in
clinical investigation
or clinical
performance
evaluation.
51. Every person, sponsor, clinical research organisation, any other organisation
or investigator conducting a clinical investigation or clinical performance
evaluation or his agent, as the case may be, shall, if so required, disclose to the
Medical Device Officer or any other officer authorised by the Central Licensing
Authority, the names, addresses and other particulars of persons involved in
conducting clinical investigation or clinical performance evaluation and similar
29
details in respect of participants in such clinical investigation or clinical
performance evaluation.
Permission to
Conduct of clinical
performance
evaluation for new
in vitro diagnostic
medical device
52. (1) No person or sponsor shall conduct any clinical performance evaluation in
respect of a new in vitro diagnostic device on specimen, including any blood or
tissue donation, derived from the human body except under, and in accordance
with, the permission granted by the Central Licensing Authority subject to such
conditions and in such form and manner as specified in these rules.
(2) An application for grant of permission to conduct, clinical performance
evaluation of new in vitro diagnostic device shall be made to the Central Licensing
Authority in Form MD22 by the sponsor and shall be accompanied with a fee as
specified in the Second Schedule and along with information specified in sub-rule
(3)duly signed by the sponsor in India:
Provided that no fee shall be required to be paid by the institutes,
organizations, hospitals run by the Central Government or State Government,
involved in conduct of clinical performance evaluation of new in vitro diagnostic
medical devices.
(3) The information specified under sub-rule (2) shall contain the following
information, namely,-
(i) approval from an Ethics Committee, which is registered with the Central
Licensing Authority, as prescribed in Appendix VII of the Seventh
Schedule;
(ii) source and quantity of all types of samples which shall be used during
evaluation;
(iii) device description including specification of raw material and finished
product, data allowing identification of the device in question, proposed
instruction for use, labels and regulatory status in other countries, if any;
(iv) in house performance evaluation data used to establish stability,
specificity, sensitivity, repeatability and reproducibility;
(v) clinical performance evaluation plan stating in particular the purpose,
scientific, technical or medical grounds, scope of evaluation and number
of devices concerned;
(vi) Case Report Form as prescribed in Appendix IV of the Seventh Schedule;
(vii) Undertaking by investigators as prescribed in Appendix VI of the Seventh
Schedule;
(viii) the list of laboratories or other institutions taking part in the evaluation
study;
(ix) the scheduled duration for evaluation and, in case of devices for self-
testing, the location and number of lay persons involved;
(x) an undertaking that the device in question conforms to the requirements of
these rules, apart from aspects covered by the evaluation and apart from
biotech
Highlight
30
those specifically itemized in the undertaking, and that every precaution
has been taken to protect the health and safety of the patient, user and
other persons.
(4) The Central Licensing Authority may, in public interest, abbreviate, defer, or
waive the requirement of conducting clinical performance evaluation for reasons to
be recorded in writing for grant of permission to import or manufacture new in
vitro diagnostic medical device for marketing.
(5) The Central Licensing Authority after being satisfied with the information
furnished along with application under sub-rule (1) may grant permission to
conduct clinical performance evaluation for anew in vitro diagnostic medical
device in Form MD23:
Provided where information, as referred to in sub-rule (3) is
inadequate, the Central Licensing Authority shall inform the applicant in writing,
within ninety days from the date of application or such extended period, not
exceeding a further period of thirty days, as the Central Licensing Authority may,
for reasons to be recorded in writing, permit, the requirements to be complied with
as before permission may be granted:
Provided further, if the applicant has not furnished the required
information sought by the Central Licensing Authority within ninety days from the
date of intimation, it may reject the application for reasons to be recorded in
writing.
Conditions for
permission to
conduct of clinical
performance
evaluation.
53. After grant of permission referred in rule 52, the following conditions shall be
complied with by the applicant,-
(i) clinical performance evaluation shall be conducted in compliance with the
approved clinical performance evaluation plan, Good Clinical Practices Guidelines;
(ii) clinical performance evaluation shall be initiated under the supervision of an
approved Ethics Committee;
(iii) clinical performance evaluation shall be registered with the Clinical Trial
Registry of India before enrolling the first patient for such clinical performance
evaluation;
(iv) annual status report of each clinical performance evaluation, as to whether it is
ongoing, completed or terminated, shall be submitted to the Central Licensing
Authority by the sponsor, and in case of termination of any clinical performance
evaluation, the detailed reasons for the same shall be communicated to the Central
Licensing Authority within 30 days of date of termination;
(v) the laboratories or other institutions taking part in the evaluation study or the
sponsor including their employees, subsidiaries and branches, their agents,
contractors and sub-contractors and clinical investigation sites shall be open to
inspection by officers of the Central Licensing Authority authorised under these
31
rules, to verify compliance of the requirements of these rules for conduct of clinical
performance evaluation.
(vi) the clinical performance evaluation shall be initiated within the period of one
year from the date of grant of permission, failing which prior permission from the
Central Licensing Authority shall be required.
(vii) the Central Licensing Authority may impose any other condition while
granting permission in respect of specific clinical performance evaluation, if
considered necessary, regarding the objective, design, subject population, subject
eligibility, assessment, conduct and treatment of clinical performance evaluation.
Suspension or
cancellation of
permission.
54. (1) If any person to whom permission is granted under sub-rule (5) of rule 52
fails to comply with any of conditions of permission, the Central Licensing
Authority may suspend the permission for such period as it thinks fit or cancel
either wholly or partly to which it relates.
(2) Any person who is aggrieved by the order passed under sub-rule (1), may within
thirty days from the date of receipt of such order, appeal to the Central
Government, and the Central Government may, after such enquiry into the matter,
as is considered necessary and after giving an opportunity of being heard, pass such
order in relation thereto as, it thinks fit.
Medical management
and compensation for
injury related to clinical
performance
evaluation.
55. Where any participant is injured on account of his participation in the clinical
performance evaluation, the sponsor permitted under rule 52 shall provide medical
management to that participant.
Performance
evaluation of in
vitro medical
devices.
56. (1)The Central Government shall, by notification, designate the Central
Government Laboratories or Central medical device testing centres, as the case
may be, to carry out performance evaluation in respect of specified in vitro
diagnostic medical devices.
(2) Performance evaluation prior to grant registration, in respect of in vitro
diagnostic medical devices, shall be carried out at the designated laboratories or
medical device testing centres under sub-rule (1).
(3) Performance evaluation of in vitro diagnostic medical devices shall be carried
out as specified by the concerned laboratory or medical device testing centre
notified under sub-rule (1).
Part VIII
Permission to import or manufacture medical device which does not have
predicate medical device
Permission to import
or manufacture
medical device of
clinical
investigation.
57. (1) Save as otherwise provided in these rules for import or manufacture of
medical device which does not have predicate medical device or has undergone
clinical investigation, an application for grant of permission for such medical
device after completion of its clinical investigation or clinical performance
evaluation, as the case may be, under Part VII shall be made to the Central
Licensing Authority in Form MD24 either by an authorised agent or a manufacturer
32
himself, as the case may be, and shall be accompanied with fee as specified in the
Second Schedule along with information specified in Part IV of the Fourth
Schedule:
Provided medical device which does not have predicate medical device
indicated in life threatening, serious diseases or diseases of special relevance to the
Indian health scenario, national emergencies, extreme urgency, epidemic and
medical devices indicated for conditions, diseases for which there is no therapy, the
animal data or clinical data requirements may be abbreviated, deferred or omitted,
as deemed appropriate by the Central Licensing Authority:
Provided further that subject to other provisions of these rules, in case
of medical device of which drugs are also a part, the submission of requirements
relating to animal toxicology, reproduction studies, teratogenic studies, perinatal
studies, mutagenicity and carcinogenicity may be relaxed in case of drugs already
approved and marketed in India and supported by adequate published evidence
regarding the safety of the drug.
(3) The Central Licensing Authority, after being satisfied, may grant permission to
import or manufacture medical device which does not have predicate medical
device or has undergone clinical investigation in Form MD25.
Permission to import
or manufacture new
in vitro diagnostic
medical device.
58. (1) An application for grant of permission to import or manufacture new in
vitro diagnostic medical device shall be made to the Central Licensing Authority in
Form MD26 either by an authorised agent or a manufacturer himself, as the case
may be, and shall be accompanied with fee as specified in the Second Schedule
along with information specified in Part IV of the Fourth Schedule:
Provided new in vitro diagnostic medical device indicated in life
threatening, serious diseases or diseases of special relevance to the Indian health
scenario, national emergencies, extreme urgency, epidemic and medical devices
indicated for conditions, diseases for which there is no therapy, the clinical data
requirements may be abbreviated, deferred or omitted, as deemed appropriate by
the Central Licensing Authority.
(3) The Central Licensing Authority, after being satisfied, may grant permission to
import or manufacture new in vitro diagnostic medical device in Form MD27.
Condition of
permission to import
or manufacture
investigational
medical device and
new in vitro
diagnostic medical
device.
59. A permission in Form MD25 or Form MD27 shall be subject to the following
conditions, namely:-
33
(1) The medical device shall conform to the specification submitted along with the
application;
(2) The permission holder shall submit the Periodic Safety Update Report to the
Central Licensing Authority from the date of launch in the market and such report
shall be submitted every six month for the first two years, followed annually two
years submission.
(3) The permission holder shall inform the date of launch of medical device in the
market to the Central Licensing Authority.
(4) The permission holder shall submit the suspected unexpected serious adverse
event within fifteen days of the awareness of the event to the Central Licensing
Authority.
(5) The label, prescribing information or package insert to be adopted for
marketing medical device in the country, shall be got approved from the Central
Licensing Authority before the medical device is marketed.
PART IX
Duties and Powers of Medical Device Officer, Medical Device Testing
Officer and Notified Body
Duties of medical
device testing
officer.
60. The Medical Device Testing Officer shall cause the sample of medical device
or portion thereof tested or evaluated as may be sent in a sealed package by the
Medical Device Officer or any other persons under provisions of Part IV, V and
VII of these rules and shall furnish the report of the result of the test or evaluation
in accordance with these rules.
Procedure to be
adopted by medical
device testing
officer on receipt of
sample.
61. (1) On receipt of the sealed package of medical device or portion thereof, from
a Medical Device Officer or any other persons for test or evaluation, the Medical
Device Testing Officer shall compare the seals on the packet or on portion thereof
with the specimen impression received separately and shall note the condition of
the seals on the packet or on portion thereof.
(2) After completion of test or evaluation, the Medical Device Testing Officer shall
forthwith furnish a report to the Medical Device Officer in triplicate in Form
MD28 of the result of the test or evaluation along with full protocols of the test or
evaluation applied.
Application for test
or evaluation of
medical device.
62. For the purpose of these rules, an application from a purchaser for test or
evaluation of a medical device or portion of medical device under section 26 of the
Act shall be made in Form MD29 and the report of such test or evaluation of the
medical device which is prepared on such application shall be supplied to the
applicant in Form MD28.
Duties of medical
device officer.
63. Subject to the instructions of the Central Licensing Authority or State Licensing
Authority, as the case may be, it shall be duty of Medical Device Officer to,-
(i) inspect not less than once in a year all establishments licensed by the Central
Licensing Authority as the case may be, for manufacturing of medical device
34
or State Licensing Authority for sale, distribution, exhibit or offer for sale of
medical device, as the case may be, within the area assigned to him;
(ii) conform that the conditions of licence are being observed;
(iii) take samples of medical device manufactured or imported for sale, or stocked
or exhibited for sale in respect of which, the Medical Device Officer has
reason to suspect contravention of the provisions of the Act or these rules and
send them for test or evaluation:
Provided that in case of large sized medical device, where in the
opinion of the Medical Device Officer, drawing samples of such a device may
not be physically practical, shall be inspected at the same place by the Medical
Device Officer with or without expert and evaluated or tested by the Medical
Device Testing Officer, for any suspect contravention, after approval of the
Central Licensing Authority or State Licensing Authority, as the case may be;
(iv) maintain a record of all inspections undertaken, drawing of samples and
seizure of stocks and action taken by Medical Device Officer in exercise and
performance of duties and to furnish copies of such record to the Central
Licensing Authority or State Licensing Authority, as the case may be;
(v) make such enquiries and inspections as may be necessary to detect the
manufacture or sale of medical device in contravention of any provision of the
Act and these rules;
(vi) investigate any complaint relating to medical device in writing which may be
made to the Medical Device Officer;
(vii) institute prosecution in relation to contravention of the provisions of the Act
and these rules;
(viii) review technical dossier of medical device furnished with the application
under these rules or any other duties assigned by the Central Licensing
Authority or State Licensing Authority, as the case may be, related to these
rules.
Prohibition of
disclosure of
information.
64. Except for the purpose of official business or when required by a Court, a
Medical Device Officer shall not, without the sanction in writing of his official
superior, disclose to any person any information acquired while exercising such
official duties.
Form of order not to
dispose of stock.
65. An order in writing by a Medical Device Officer under clause (c) of sub-section
(1) of section 22 of the Act requiring a person not to dispose of any stock in his
possession shall be in Form MD30.
Prohibition of sale. 66. No person in possession of a medical device in respect of which a Medical
Device Officer has made an order under clause (c) of sub-section (1) of section 22
of the Act shall, in contravention of that order, sell or otherwise dispose of any
stock of such medical device.
35
Form of receipt for
seized medical
devices, record,
register, documents
or any other material
objects.
67. A receipt by a Medical Device Officer for the stock of any medical device or
for any record, register, document or any other material object seized under clause
(c) or clause (cc) of sub-section (1) of section 22 of the Act shall be in Form
MD31.
Manner of certifying
copies of seized
documents.
68. The Medical Device Officer shall return the document, seized under section 22
of the Act, within a period of twenty days from the date of such seizure, to the
person from whom they were recovered or produced, after copies thereof or
extracts therefrom have been signed by the concerned Medical Device Officer and
the person from whom they were recovered or produced.
Form of intimation
of purpose of taking
samples.
69. When a Medical Device Officer takes a sample of a medical device other than
medical device specified in proviso to sub-rule (iii) of rule 63 for the purpose of
test or evaluation, Medical Device Officer shall inform such purpose in writing in
Form MD32 to the person from whom it takes and shall tender the fair price
thereof under a written acknowledgement.
Form of receipt for
samples of medical
devices where fair
price tendered is
refused.
70. Where the fair price tendered under sub-section (1) of section 23 of the Act for
sample of medical device or portion thereof taken for the purposes of test or
evaluation has been refused by the person from whom such sample has been taken,
the Medical Device Officer shall tender a receipt thereof to such person in Form
MD33.
Procedure for
dispatch of sample
to medical device
testing officer.
71. (1) The sample of medical device or portion thereof sent by Medical Device
Officer to the Medical Device Testing Officer for test or evaluation under sub-
section (4) of section 23 of the Act shall be sent by registered post or by hand in a
sealed packet, enclosed together with a memorandum in Form MD34, in an outer
cover addressed to the Medical Device Testing Officer.
(2) A copy of the memorandum and a specimen impression of the seal used to seal
the packet shall be sent to the Medical Device Testing Officer separately by
registered post or handed over by hand and a copy of the memorandum shall be
endorsed to the manufacturer.
Confiscation of
medical devices,
implements,
machinery, etc.
72. (1) Where any person has been convicted for contravening any of the
provisions of the Act or any rule made thereunder, the stock of medical device in
respect of which the contravention has been made shall be liable to confiscation.
(2) Where any person has been convicted for manufacturing any medical device
notified under sub clause (iv) of clause (b) of section 3 of the Act, which is deemed
to be misbranded, adulterated or spurious, for sale, stocking or exhibiting for sale or
distribution without a valid licence or licence, any implements or machinery used
in such manufacture, sale or distribution and any receptable, package or covering in
which such medical device is contained and the animals, vehicles, vessels or other
conveyances used in carrying such medical device shall be liable to confiscation.
Procedure for
disposal of
confiscated medical
device.
73. (1) The Court may refer the confiscated medical device to the Medical Device
Officer concerned for report as to whether they are of standard quality or
36
contravene the provisions of the Act or the rules in any respect.
(2) If the Medical Device Officer, on the basis of Medical Device Testing Officer’s
report, finds the confiscated medical device to be not of standard quality or to
contravene any of the provisions of the Act or rules made thereunder, Medical
Device Officer shall, with the approval of the Central Licensing Authority or State
Licensing Authority, as the case may be, report to the Court accordingly. The Court
shall thereupon order destruction of such medical devices. The destruction shall
take place under the supervision of the Medical Device
Previous and next
Questions people ask
Is form MD4 of the Medical Device Rules, 2016. still in force?
No repeal of the Medical Device Rules, 2016. is recorded.